Literature DB >> 23165329

Dosing of antibiotics in critically ill patients: are we left to wander in the dark?

Joanna Matuszkiewicz-Rowińska1, Jolanta Małyszko, Ewa Wojtaszek, Paweł Kulicki.   

Abstract

Critically ill patients are frequently affected by acute kidney injury accompanied by dysfunction of other systems and organs. Sepsis is common in this population and remains a major cause of multiorgan dysfunction syndrome, indicating a crucial role in efficient antibiotic treatment. However, such treatment is particularly difficult due to altered pharmacokinetic profile in these patients, dynamic changes in their clinical status and, in many cases, need for renal replacement therapy (RRT). Current guidelines concerning the dosing of antibiotics in this patient population are not particularly reliable because they are based on studies involving small and heterogeneous groups of patients, often treated with different RRT modalities. Our paper reviews the basic pharmacokinetic and pharmacodynamic parameters as well as other factors that should be considered while devising a proper therapeutic approach for this patient population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23165329     DOI: 10.20452/pamw.1541

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  3 in total

1.  Pediatric pharmaceutical care with anti-infective medication in a patient with acute hematogenous osteomyelitis caused by methicillin-resistant Staphylococcus aureus.

Authors:  Chanmei Lv; Jiantao Lv; Yue Liu; Qifeng Liu; Dongna Zou
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

2.  Pharmacokinetic profile of defibrotide in patients with renal impairment.

Authors:  Paola Tocchetti; Elena Tudone; Jean-Francois Marier; Thomas C Marbury; Katie Zomorodi; Mark Eller
Journal:  Drug Des Devel Ther       Date:  2016-08-16       Impact factor: 4.162

Review 3.  Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.

Authors:  Rui Pedro Veiga; José-Artur Paiva
Journal:  Crit Care       Date:  2018-09-24       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.